Halo's lead program, H01, is a small-molecule first-in-class inhibitor of HA synthesis under development for conditions including pulmonary hypertension, IPF, and primary sclerosing cholangitis.  A Phase I study was recently completed at Stanford University.

Our pipeline of proprietary compounds targeting extra cellular matrix editing are in various stages of discovery and preclinical development.  Our partnership with Stanford University and the Paul Bollyky Lab serves as the anchor for drug candidate discovery and lead optimization.